Partner Spotlight: Kymera and Sanofi chase “undruggable” targets in immunology

In 2020, Sanofi announced its partnership with Kymera Therapeutics, combining Sanofi’s resources and industry experience with the emerging biotech’s expertise in targeted protein degradation (TPD) aiming to create new options for patients struggling with immunological and inflammatory (I&I) conditions.

"For us at Kymera, the immediate future is immunology – solving big problems with small molecules," said Nello Mainolfi, Kymera Therapeutics' CEO.

• Read More